“I am very happy that Allan Gabor, who has extensive management experience, also in China, will be taking on this important task in one of the most important regional markets for our company,” said Kai Beckmann, CEO Performance Materials and Executive Board member responsible for Asia.
The change is part of a realignment of the entire business sector, which under the leadership of Beckmann has developed a strategy to sharpen its focus on markets and customers. The OLED materials business will be combined with the Liquid Crystals business into a single business unit. In addition, all activities pertaining to research, business development and external partnerships will be united in a central research and innovation unit. Production and supply chain activities will also be realigned.
Gabor has been working for Merck KGaA since 2013 and serves as the head of the Biopharma business in Asia, including China. He has more than 25 years of management experience in leadership roles in countries such as China, Turkey, Russia, and the US. Prior to joining Merck KGaA, he was head of Pfizer in China, where he has been working since 1999.